Home

Travere Therapeutics, Inc. - Common Stock (TVTX)

20.46
-0.59 (-2.80%)

Travere Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly those associated with kidney disorders

The company’s mission is to address significant unmet medical needs and improve the quality of life for individuals affected by these conditions. By leveraging advanced research and development capabilities, Travere aims to deliver targeted treatments that can help manage or potentially reshape the course of rare kidney diseases, ultimately striving to empower patients and their families through effective therapeutic options.

SummaryNewsPress ReleasesChartHistoricalFAQ
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.investors.com
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via Investor's Business Daily · January 9, 2025
3 Under-the-Radar Healthcare Companies
While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains.
Via MarketBeat · November 11, 2024
A Preview Of Travere Therapeutics's Earningsbenzinga.com
Via Benzinga · October 30, 2024
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'benzinga.com
Jim Cramer warns Travere Therapeutics is losing a ton of money. He advises holding onto Palantir as a spec and expects good news from Stanley Black & Decker.
Via Benzinga · October 23, 2024
Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)benzinga.com
Via Benzinga · October 21, 2024
Breaking Down Travere Therapeutics: 23 Analysts Share Their Viewsbenzinga.com
Via Benzinga · October 16, 2024
Top 2 Health Care Stocks That Are Ticking Portfolio Bombsbenzinga.com
Via Benzinga · October 10, 2024
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · October 17, 2024
Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Diseaseinvestors.com
The company could soon ask for approval of its only drug, Filspari, in a second disease.
Via Investor's Business Daily · October 9, 2024
Where Travere Therapeutics Stands With Analystsbenzinga.com
Via Benzinga · September 27, 2024
Micron To $150? Here Are 10 Top Analyst Forecasts For Fridaybenzinga.com
Via Benzinga · September 27, 2024
Costco, Scholastic And 3 Stocks To Watch Heading Into Fridaybenzinga.com
Via Benzinga · September 27, 2024
Analyst Ratings For Travere Therapeuticsbenzinga.com
Via Benzinga · September 6, 2024
Expert Ratings For Travere Therapeuticsbenzinga.com
Via Benzinga · August 2, 2024
Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analystsbenzinga.com
Via Benzinga · May 7, 2024
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Knowbenzinga.com
Via Benzinga · April 17, 2024
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · September 26, 2024
This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Mondaybenzinga.com
Via Benzinga · September 9, 2024
Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Fridaybenzinga.com
Via Benzinga · September 6, 2024
Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Diseaseinvestors.com
The company previously had an accelerated approval for its IgA nephropathy treatment.
Via Investor's Business Daily · September 6, 2024
NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Fridaybenzinga.com
Via Benzinga · September 6, 2024
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Dealtalkmarkets.com
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus royalties.
Via Talk Markets · July 27, 2024
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · July 10, 2024
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesdaybenzinga.com
Via Benzinga · July 9, 2024
TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024investorplace.com
TVTX stock results show that Travere Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 6, 2024